New stock news | Lu Daopei Medical Hong Kong IPO prospectus fails: the leading enterprise in domestic hematology medical treatment.

Ludaopei Medical Group (referred to as Ludaopei Medical) submitted its Hong Kong IPO prospectus on January 31, 2024, which expired on July 31 after 6 months. CITIC SEC, CICC International, and Macquarie were its joint sponsors when the prospectus was submitted. According to Frost & Sullivan data, in terms of revenue in 2022, Ludaopei Medical is the largest provider of blood disease medical services in China, with a market share of 6.4%. As of December 31, 2022, the company had the highest number of registered beds for blood disease patients and HSCT (hematopoietic stem cell transplantation) positions. Based on the same data source, in terms of the number of hematopoietic stem cell transplants in 2022, the company is the second largest participant in China, with a market share of 6.6%. In China's hematopoietic stem cell transplantation service market in 2022, the company was the largest participant in allogeneic hematopoietic stem cell transplantation, with a market share of 9.4%, and the second largest in half-matched hematopoietic stem cell transplantation, with a market share of 10.2%. In terms of revenue generated from blood disease special inspection services in 2022, the company is also one of the top three providers in China, with a market share of 7.8%. Financially, as of September 30 in 2020, 2021, 2022, and 2023, Ludaopei Medical achieved revenues of approximately 1.162 billion yuan, 1.370 billion yuan, 1.677 billion yuan, and 1.421 billion yuan respectively; during the same periods, it incurred losses of approximately 122 million yuan, 408 million yuan, 547 million yuan, and 88.029 million yuan respectively.